Axcan Is Buying European Specialty Pharma Eurand For $583Mx
At a 9% premium to Eurand's closing stock price Nov. 30, the value is disappointing, but majority investor Warburg Pincus favors the deal and competitive bids are unlikely.
At a 9% premium to Eurand's closing stock price Nov. 30, the value is disappointing, but majority investor Warburg Pincus favors the deal and competitive bids are unlikely.